China Medical System: First Prescriptions for Innovative Drug Lumeblue® Issued in China SHENZHEN, CHINA, Dec. 08, 2024 (GLOBE NEWSWIRE) -- On 6 December, China Medical System Holdings Limited (“CMS” or…
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia SHENZHEN, CHINA, Dec. 02, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its…
China Medical System: NDA for Additional Rheumatoid Arthritis Indication of Methotrexate Injection Approved in China SHENZHEN, CHINA, Aug. 05, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its…
China Medical System Completes Dosing of the First Subject in Phase III Bridging Trial of Ruxolitinib Cream in Atopic Dermatitis in China SHENZHEN, CHINA, June 25, 2024 (GLOBE NEWSWIRE) -- On June 25, China Medical System Holdings Limited (the “Company”,…
CMS and Incyte Announce Collaboration and License Agreement for Povorcitinib in China and Southeast Asia HONG KONG, China and WILMINGTON, Del., April 01, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (“CMS”…